| Dr David M Schull, MD | |
|
645 Mcqueen Smith Rd N Ste 205, Prattville, AL 36066-7269 | |
| (334) 568-4740 | |
| (334) 568-4741 |
| Full Name | Dr David M Schull |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 39 Years |
| Location | 645 Mcqueen Smith Rd N Ste 205, Prattville, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750300356 | NPI | - | NPPES |
| 3808117 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD0000028925 (Tennessee) | Secondary |
| 208800000X | Urology | 13679 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prattville Baptist Hospital | Prattville, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Health Care Authority For Baptist Health, An Affiliate Of Uabhs | 8426076670 | 179 |
News Archive
In a study of 1000 adult patients with unplanned admission to a tertiary hospital in Singapore, the prevalence of adverse drug reactions (ADRs) at the time of admission was 12.4 percent, and the prevalence of ADRs causing admission to the hospital was 8.1 percent.
The researchers Wasco Wruck and Prof. James Adjaye from the Institute of Stem Cell Research and Regenerative Medicine, Medical Faculty of Heinrich-Heine-University Duesseldorf, Germany, employed a bioinformatic approach on transcriptome data pertaining to human lung epithelial cells infected with SARS-CoV-2.
The holiday season is officially in full gear and with it comes the tempting Thanksgiving-to-New-Year's food fest. While research shows that the average person really only gains about a pound over the course of the holidays, it can still have a big cumulative effect on waistlines. That's because the extra weight usually doesn't come off the following year.
Over the years, the Centers for Disease Control and its partners have made major progress towards reducing lead exposure in the United States. But more work remains in preventing lead poisoning in US children and adults, according to a special supplement to the Journal of Public Health Management and Practice. The journal is published in the Lippincott portfolio by Wolters Kluwer.
LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.
› Verified 9 days ago
| Entity Name | Health Care Authority For Baptist Health, An Affiliate Of Uabhs |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982653390 PECOS PAC ID: 8426076670 Enrollment ID: O20060220000538 |
News Archive
In a study of 1000 adult patients with unplanned admission to a tertiary hospital in Singapore, the prevalence of adverse drug reactions (ADRs) at the time of admission was 12.4 percent, and the prevalence of ADRs causing admission to the hospital was 8.1 percent.
The researchers Wasco Wruck and Prof. James Adjaye from the Institute of Stem Cell Research and Regenerative Medicine, Medical Faculty of Heinrich-Heine-University Duesseldorf, Germany, employed a bioinformatic approach on transcriptome data pertaining to human lung epithelial cells infected with SARS-CoV-2.
The holiday season is officially in full gear and with it comes the tempting Thanksgiving-to-New-Year's food fest. While research shows that the average person really only gains about a pound over the course of the holidays, it can still have a big cumulative effect on waistlines. That's because the extra weight usually doesn't come off the following year.
Over the years, the Centers for Disease Control and its partners have made major progress towards reducing lead exposure in the United States. But more work remains in preventing lead poisoning in US children and adults, according to a special supplement to the Journal of Public Health Management and Practice. The journal is published in the Lippincott portfolio by Wolters Kluwer.
LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David M Schull, MD 301 Brown Springs Rd, Montgomery, AL 36117-7005 Ph: (334) 747-4159 | Dr David M Schull, MD 645 Mcqueen Smith Rd N Ste 205, Prattville, AL 36066-7269 Ph: (334) 568-4740 |
News Archive
In a study of 1000 adult patients with unplanned admission to a tertiary hospital in Singapore, the prevalence of adverse drug reactions (ADRs) at the time of admission was 12.4 percent, and the prevalence of ADRs causing admission to the hospital was 8.1 percent.
The researchers Wasco Wruck and Prof. James Adjaye from the Institute of Stem Cell Research and Regenerative Medicine, Medical Faculty of Heinrich-Heine-University Duesseldorf, Germany, employed a bioinformatic approach on transcriptome data pertaining to human lung epithelial cells infected with SARS-CoV-2.
The holiday season is officially in full gear and with it comes the tempting Thanksgiving-to-New-Year's food fest. While research shows that the average person really only gains about a pound over the course of the holidays, it can still have a big cumulative effect on waistlines. That's because the extra weight usually doesn't come off the following year.
Over the years, the Centers for Disease Control and its partners have made major progress towards reducing lead exposure in the United States. But more work remains in preventing lead poisoning in US children and adults, according to a special supplement to the Journal of Public Health Management and Practice. The journal is published in the Lippincott portfolio by Wolters Kluwer.
LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.
› Verified 9 days ago